In the design of paediatric PK and safety studies, use weight-based dosing and enroll all children above 4 weeks concurrently, unless a strong rationale exists for not doing so.
Pharmaceutical companies
Sub-Actions & Milestones

Use weight-based dosing and enroll all children above 4 weeks concurrently in the design of paediatric PK and safety studies

Pharmceutical Companies

-

-

-

-

-

-

-

-

-

-

Updates

Notes

Responsible